Emergent Biosolutions EBS Gross Profit

Gross Profit at other companies

SIGA TechnologiesSIGA

$23.44M-57.8%

AMP

Amphastar PharmaceuticalsAMPH

$93.47M+8.1%

Amneal Pharmaceuticals, Inc.AMRX

$334.51M+16.9%

Lifecore Biomedical, Inc.LFCR

$12.08M—

Rapid Micro BiosystemsRPID

$1.21M+341%

Cumberland PharmaceuticalsCPIX

$7.2M-30.0%

FAQ

What is Emergent Biosolutions's gross profit?

Emergent Biosolutions (EBS) reported gross profit of $137.2M in Q2 2026.

How has Emergent Biosolutions's gross profit changed year-over-year?

Emergent Biosolutions's gross profit increased by 85.4% year-over-year, from $74M to $137.2M.

What is the long-term trend for Emergent Biosolutions's gross profit?

Over 3 years (2022 to 2025), Emergent Biosolutions's gross profit has grown at a -0.6% compound annual growth rate (CAGR), from $424.1M to $416.7M.

What does gross profit mean?

Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.